Cargando…
The NAMPT Inhibitor FK866 Increases Metformin Sensitivity in Pancreatic Cancer Cells
SIMPLE SUMMARY: Use of the antidiabetic drug metformin as a single antitumor agent has been disappointing in clinics. We sought to explain why cancer cells adapt to metformin treatment and to develop more effective drug combinations. We found that the antitumor actions of metformin involved a reduct...
Autores principales: | Parisotto, Maxime, Vuong-Robillard, Nhung, Kalegari, Paloma, Meharwade, Thulaj, Joumier, Loick, Igelmann, Sebastian, Bourdeau, Véronique, Rowell, Marie-Camille, Pollak, Michael, Malleshaiah, Mohan, Schmitzer, Andréea, Ferbeyre, Gerardo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688551/ https://www.ncbi.nlm.nih.gov/pubmed/36428689 http://dx.doi.org/10.3390/cancers14225597 |
Ejemplares similares
-
The NAMPT inhibitor FK866 reverts the damage in spinal cord injury
por: Esposito, Emanuela, et al.
Publicado: (2012) -
A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT
por: Barraud, Marine, et al.
Publicado: (2016) -
The NAMPT Inhibitor FK866 in Combination with Cisplatin Reduces Cholangiocarcinoma Cells Growth
por: Pant, Kishor, et al.
Publicado: (2023) -
Circumventing senescence is associated with stem cell properties and metformin sensitivity
por: Deschênes‐Simard, Xavier, et al.
Publicado: (2019) -
Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells
por: Thakur, Basant Kumar, et al.
Publicado: (2013)